🇺🇸 Ketorolac Ophthalmic Solution in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 4
Most-reported reactions
- Dyspnoea — 1 report (25%)
- Instillation Site Pain — 1 report (25%)
- Lacrimation Increased — 1 report (25%)
- Product Substitution Issue — 1 report (25%)
Other Ophthalmology approved in United States
Frequently asked questions
Is Ketorolac Ophthalmic Solution approved in United States?
Ketorolac Ophthalmic Solution does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ketorolac Ophthalmic Solution in United States?
Bausch & Lomb Incorporated is the originator. The local marketing authorisation holder may differ — check the official source linked above.